Compare EVC & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVC | FHTX |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.8M | 246.6M |
| IPO Year | 2000 | 2020 |
| Metric | EVC | FHTX |
|---|---|---|
| Price | $2.73 | $4.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $11.86 |
| AVG Volume (30 Days) | ★ 335.2K | 196.2K |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | ★ 7.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $420,178,000.00 | $24,518,000.00 |
| Revenue This Year | $64.06 | $47.50 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 24.96 | N/A |
| 52 Week Low | $1.58 | $2.95 |
| 52 Week High | $3.15 | $7.42 |
| Indicator | EVC | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.75 | 47.16 |
| Support Level | $2.75 | $4.27 |
| Resistance Level | $2.85 | $4.87 |
| Average True Range (ATR) | 0.11 | 0.38 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 60.94 | 7.77 |
Entravision Communications Corp owns and operates Spanish language television and radio stations in the United States. The Company also owns and operates a smaller group of television stations that broadcast English language programming and has operations that provide programmatic advertising technology and services. The Company has organized its operations into two reportable segments. Its media segment includes its television, radio, and digital marketing operations. Its advertising and technology services segment provides programmatic advertising and technology services. The company generates the majority of its revenue from the Media segment. Geographically, the company generates the majority of its revenue from the United States.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.